相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Accuracy of gamma-glutamyl transpeptidase-to-platelet ratio (GPR), red cell distribution width (RDW), aspartate aminotransferase-to-platelet ratio index (APRI), and the fibrosis-4 index (FIB4) compared with liver biopsy in patients with drug-induced liver injury (DILI)
Minjie Wan et al.
MEDICINE (2021)
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
Frank Tacke et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
HEPATOLOGY (2020)
Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells
Alberto Marti-Rodrigo et al.
GUT (2020)
WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice
Ying-sheng Gao et al.
ACTA PHARMACOLOGICA SINICA (2020)
The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway
Siwei Tan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
Quentin M. Anstee et al.
CONTEMPORARY CLINICAL TRIALS (2020)
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Marcos Pedrosa et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
Cristy R. C. Verzijl et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Naga Chalasani et al.
GASTROENTEROLOGY (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
Guifang Du et al.
CELL DEATH & DISEASE (2020)
Src Inhibition Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation and Decreasing Connective Tissue Growth Factor
Hye-Young Seo et al.
CELLS (2020)
Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-κB pathway
Yan Liu et al.
AGING-US (2020)
Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/MAPK Pathway of Hepatic Stellate Cells
Young-Chan Yoon et al.
BIOMOLECULES & THERAPEUTICS (2020)
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Natascha Roehlen et al.
CELLS (2020)
Crocin attenuates CCl4-induced liver fibrosis via PPAR-γ mediated modulation of inflammation and fibrogenesis in rats
J. Chhimwal et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2020)
ROS-dependent inhibition of the PI3K/Akt/mTOR signaling is required for Oroxylin A to exert anti-inflammatory activity in liver fibrosis
Min Shen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Trenton T. Ross et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2020)
Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study
Jorge Luis Poo et al.
HEPATOLOGY INTERNATIONAL (2020)
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo
Catherine T. Frenette et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Burden of liver diseases in the world
Sumeet K. Asrani et al.
JOURNAL OF HEPATOLOGY (2019)
Methyl ferulic acid attenuates liver fibrosis and hepatic stellate cell activation through the TGF-β1/Smad and NOX4/ROS pathways
Qi Cheng et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2019)
Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis in Mice in a Model-Dependent Manner
Raphael P. H. Meier et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
MicroRNA-101 suppresses liver fibrosis by downregulating PI3K/Akt/mTOR signaling pathway
Yang Lei et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2019)
Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell
Hanyan Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®
John O. Link et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
Arun J. Sanyal et al.
HEPATOLOGY (2019)
Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targeting the TGF-β1/Smad and MAPK signaling pathways
Yu Peng et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance
Uma Kavita et al.
AAPS JOURNAL (2019)
RAP-8 ameliorates liver fibrosis by modulating cell cycle and oxidative stress
Hongjiao Xu et al.
LIFE SCIENCES (2019)
Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-κB-TNF-α signaling pathway in a PPARγ-dependent manner
Zhuo Wei et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Praziquantel ameliorates CCl4-induced liver fibrosis in mice by inhibiting TGF-β/Smad signalling via up-regulating Smad7 in hepatic stellate cells
Jinfeng Liu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
Vlad Ratziu et al.
CONTEMPORARY CLINICAL TRIALS (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Deficiency of Both Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice
Jessica M. Ferrell et al.
HEPATOLOGY (2019)
Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3
Yuan-Yuan Fan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice
Mostafa M. Salah et al.
LIFE SCIENCES (2019)
Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism
Jordi Gracia-Sancho et al.
HEPATOLOGY COMMUNICATIONS (2019)
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
Rohit Loomba et al.
HEPATOLOGY (2018)
Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis
Yoon Ok Jang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Inhibition of canonical WNT signaling pathway by β-catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12
Busra Ozturk Akcora et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) and liver fibrosis: A review
Keywan Mortezaee
CELL BIOCHEMISTRY AND FUNCTION (2018)
Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment
Sheng-Di Wu et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2018)
Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
Frank Tacke
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
Asiatic acid attenuates CCl4-induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways
Liwen Wei et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2018)
Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse
Oleksii Seniutkin et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2018)
Liver fibrosis
M. Merve Aydin et al.
TURKISH JOURNAL OF GASTROENTEROLOGY (2018)
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
Toshihiro Goto et al.
SCIENTIFIC REPORTS (2018)
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
Yun-Chieh Sung et al.
THERANOSTICS (2018)
Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases
Hee-Won Moon et al.
ANNALS OF LABORATORY MEDICINE (2018)
Octreotide attenuates hepatic fibrosis and hepatic stellate cells proliferation and activation by inhibiting Wnt/β-catenin signaling pathway, c-Myc and cyclin D1
Chong Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Selective deletion of hepatocyte platelet-derived growth factor receptor and development of liver fibrosis in mice
Beom Jin Lim et al.
CELL COMMUNICATION AND SIGNALING (2018)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
GASTROENTEROLOGY (2018)
Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs
Koji Nishikawa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile Inflammation in the Liver
Sabine Mihm
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-beta/Smad signaling pathway
Mao Mu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
Hong Wang et al.
EBIOMEDICINE (2018)
Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study
Yani Liu et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C (Reprinted from The Medical Letter on Drugs and Therapeutics, vol 58, 107-109, 2016)
Mark Abramowicz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Philipp Schwabl et al.
JOURNAL OF HEPATOLOGY (2017)
Prevention of TGF-β-induced early liver fibrosis by a maleic acid derivative antioxidant through suppression of ROS, inflammation and hepatic stellate cells activation
Kun-Lin Yang et al.
PLOS ONE (2017)
Regression of Liver Fibrosis
Lara Campana et al.
SEMINARS IN LIVER DISEASE (2017)
Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease
Wenjing Luo et al.
SCIENTIFIC REPORTS (2017)
Selective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model
Yuko Tokunaga et al.
SCIENTIFIC REPORTS (2017)
Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial
Kiminori Kimura et al.
EBIOMEDICINE (2017)
Reversal of liver fibrosis: From fiction to reality
Miguel Eugenio Zoubek et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2017)
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
S. A. Harrison et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
Scott Friedman et al.
CONTEMPORARY CLINICAL TRIALS (2016)
The PDGF system and its antagonists in liver fibrosis
Erawan Borkham-Kamphorst et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2016)
Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir
Sebastian Bernuth et al.
DIGESTIVE AND LIVER DISEASE (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Dihydroartemisinin Prevents Liver Fibrosis in Bile Duct Ligated Rats by Inducing Hepatic Stellate Cell Apoptosis through Modulating the PI3K/Akt Pathway
Qin Chen et al.
IUBMB LIFE (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial
Eric G. Meissner et al.
LIVER INTERNATIONAL (2016)
Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways
Pengfei Xu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2016)
Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis
Xing Li et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2016)
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Eric Lefebvre et al.
PLOS ONE (2016)
Specific hepatic delivery of procollagen 1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis
Carolina Jimenez Calvente et al.
HEPATOLOGY (2015)
Therapeutic administration of an ingredient of aged-garlic extracts, S-allyl cysteine resolves liver fibrosis established by carbon tetrachloride in rats
Shintaro Kodai et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Identification of a novel TGF-β-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis
Chunxian Zeng et al.
ONCOTARGET (2015)
The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
Fernando J. Barreyro et al.
LIVER INTERNATIONAL (2015)
microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway
Jia Wang et al.
ONCOTARGET (2015)
Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight
Gamal E. Shiha et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2014)
Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner
Iwona Cicha et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation
Wen-Song Ge et al.
MOLECULAR MEDICINE REPORTS (2014)
De nova lipogenesis in health and disease
Fatima Ameer et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury
Maryna Perepelyuk et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2013)
Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation
John P. Iredale et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Dissecting the role of CB1 receptors on chronic liver diseases
Ramon Bataller et al.
GUT (2013)
Preventive Effect of Halofuginone on Concanavalin A-Induced Liver Fibrosis
Jie Liang et al.
PLOS ONE (2013)
Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo
Joy X. Jiang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Nicotinamide Adenine Dinucleotide Phosphate Oxidase in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent
Tomonori Aoyama et al.
HEPATOLOGY (2012)
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis
Ferdinando A. Giannone et al.
LABORATORY INVESTIGATION (2012)
Suppression of CB1 Cannabinoid Receptor by Lentivirus Mediated Small Interfering RNA Ameliorates Hepatic Fibrosis in Rats
Si-Wen Chen et al.
PLOS ONE (2012)
Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques
Frank Tacke et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Elevated TGF-beta 1 levels might protect HCV/HIV-coinfected patients from liver fibrosis
Norma I. Rallon et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2011)
Histological regression of liver fibrosis with immunosuppressive therapy in autoimmune hepatitis
Jose Miguel Valera et al.
GASTROENTEROLOGIA Y HEPATOLOGIA (2011)
Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
Tomoyuki Iwasaki et al.
HEPATO-GASTROENTEROLOGY (2011)
Downregulation effects of beta-elemene on the levels of plasma endotoxin, serum TNF-alpha, and hepatic CD14 expression in rats with liver fibrosis
Jianguo Liu et al.
Frontiers of Medicine (2011)
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use
Anders Boyd et al.
ANTIVIRAL THERAPY (2010)
Src Is a Major Signaling Component for CTGF Induction by TGF-β1 in Osteoblasts
X. Zhang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
Marie-Luise Berres et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Fraxinus rhynchophylla ethanol extract attenuates carbon tetrachloride-induced liver fibrosis in rats via down-regulating the expressions of uPA, MMP-2, MMP-9 and TIMP-1
Wen-Huang Peng et al.
JOURNAL OF ETHNOPHARMACOLOGY (2010)
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis
Yan Wang et al.
JOURNAL OF HEPATOLOGY (2010)
Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitis
Sebastian Mueller et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Update on the pathophysiology of liver fibrosis
Massimo Pinzani et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2010)
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C
Jordi Colmenero et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial
Juan G. Abraldes et al.
GASTROENTEROLOGY (2009)
Pan-Caspase Inhibitor VX-166 Reduces Fibrosis in an Animal Model of Nonalcoholic Steatohepatitis
Rafal P. Witek et al.
HEPATOLOGY (2009)
Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production
Kyoko Toda et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis
E. Kovalenko et al.
JOURNAL OF VIRAL HEPATITIS (2009)
TGF-β1 Gene Silencing for Treating Liver Fibrosis
Kun Cheng et al.
MOLECULAR PHARMACEUTICS (2009)
Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-κB and ERK signalling
A. Chen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Non-alcoholic fatty liver disease: The mist gradually clears
Nimantha Mark Wilfred de Alwis et al.
JOURNAL OF HEPATOLOGY (2008)
Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone
Yasushi Sato et al.
NATURE BIOTECHNOLOGY (2008)
NOX in liver fibrosis
Sarnuele De Minicis et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2007)
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Fatima Teixeira-Clerc et al.
NATURE MEDICINE (2006)
Mechanisms of liver injury.: I.: TNF-α-induced liver injury:: role of IKK, JNK, and ROS pathways
RF Schwabe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Smad-dependent and Smad-independent pathways in TGF-β family signalling
R Derynck et al.
NATURE (2003)
Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats
R Bruck et al.
HEPATOLOGY (2001)
分享论文
